Potential targeted therapies for ovarian cancer beyond PARP inhibitors

Yagmur Sisman; Dan Hogdall; Tine Henrichsen Schnack; Claus Hogdall; Estrid Hogdall

doi:10.22514/ejgo.2025.030

Potential targeted therapies for ovarian cancer beyond PARP inhibitors

Yagmur Sisman^*, Dan Hogdall, Tine Henrichsen Schnack, Claus Hogdall, Estrid Hogdall

^*Corresponding author af dette arbejde

Originalsprog	Engelsk
Tidsskrift	European journal of gynaecological oncology
Vol/bind	46
Udgave nummer	3
Sider (fra-til)	1-7
Antal sider	7
ISSN	0392-2936
DOI	https://doi.org/10.22514/ejgo.2025.030
Status	Udgivet - mar. 2025

Adgang til dokumentet

10.22514/ejgo.2025.030Licens: CC BY

Andre filer og links

Se post i Web of Science

Citationsformater

@article{b578dabd6b9746518310fb353fd636e7,

title = "Potential targeted therapies for ovarian cancer beyond PARP inhibitors",

keywords = "Genetic testing, Ovarian epithelial cancer, Ovarian neoplasm, Precision medicine, Target therapy",

author = "Yagmur Sisman and Dan Hogdall and Schnack, {Tine Henrichsen} and Claus Hogdall and Estrid Hogdall",

year = "2025",

month = mar,

doi = "10.22514/ejgo.2025.030",

language = "English",

volume = "46",

pages = "1--7",

journal = "European journal of gynaecological oncology",

issn = "0392-2936",

publisher = "MRE Press",

number = "3",

}

TY - JOUR

T1 - Potential targeted therapies for ovarian cancer beyond PARP inhibitors

AU - Sisman, Yagmur

AU - Hogdall, Dan

AU - Schnack, Tine Henrichsen

AU - Hogdall, Claus

AU - Hogdall, Estrid

PY - 2025/3

Y1 - 2025/3

KW - Genetic testing

KW - Ovarian epithelial cancer

KW - Ovarian neoplasm

KW - Precision medicine

KW - Target therapy

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=cuh_wos_api&SrcAuth=WosAPI&KeyUT=WOS:001446037500001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.22514/ejgo.2025.030

DO - 10.22514/ejgo.2025.030

M3 - Review

SN - 0392-2936

VL - 46

SP - 1

EP - 7

JO - European journal of gynaecological oncology

JF - European journal of gynaecological oncology

IS - 3

ER -